A cross-sectional study on vision-related quality of life in patients with ocular GvHD

Pezzotta, S; Rossi, G C; Scudeller, L; Antoniazzi, E; Bianchi, P E; Perotti, C; Del Fante, C
September 2015
Bone Marrow Transplantation;Sep2015, Vol. 50 Issue 9, p1224
Academic Journal
Ocular GvHD affects about 40-60% of patients receiving bone marrow transplantation. Ocular complaints worsen quality of life (QoL), which, besides survival time, is a primary end point in a patient's follow-up. The aim of our study was to assess the ocular surface status and vision-related QoL (VRQoL) and explore the potential determinants in VRQoL in patients with chronic GvHD with ocular involvement. In this cross-sectional study, we investigated 40 patients with ocular GvHD after allogeneic hematopoietic stem cell transplantation assessing ocular symptoms and signs, VRQoL and ophthalmologic parameters. The median age was 52.1 years; 32.5% were females. Most of them presented a multiple organ involvement. Ophthalmological parameter examinations were on average abnormal. Corneal staining was severe/very severe in 25%; conjunctival staining in 10% of subjects. The worse QoL scores were on 'general vision', 'ocular pain', 'vision-specific mental health' and 'vision-specific role difficulties'. Both symptoms and sign scores indicate poor VRQoL. A lower VRQoL was related to schooling level, job position, underlying disease and extracorporeal photopheresis. Corneal staining, Schirmer and tear film breakup time were negatively associated to visual function-related subscales. An accurate ophthalmological and VRQoL assessment should be mandatory for a long time to promptly recognize early signs of ocular suffering, and to prevent irreversible ocular complications.


Related Articles

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • 23. Selected Aspects.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS237 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S237–S240. DOI: 10.1038/sj/bmt/1703492

  • Blood and marrow transplantation and nutritional support.  // Supportive Care in Cancer;May2010, Vol. 18 Issue 0, p57 

    Introduction Undernourishment on hospital admission has been considered as risk factor for complications and increased relapse/nonrelapse mortality in hematopoietic stem cell transplantation (HSCT) patients. Materials and methods All patients undergoing HSCT are at an increased risk for...

  • Hematopoietic stem cell transplantation in Lebanon: first comprehensive report. Bazarbachi, A.; Hatoum, H. A.; Mugharbel, A.; Otrock, Z. K.; Yassine, N.; Muwakkit, S.; Salem, Z.; Shebbo, W.; Jisr, T.; Abboud, M.; Ibrahim, A. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS96 

    Hematopoietic SCT (HSCT) has become a curative therapeutic strategy for several malignant and nonmalignant diseases. We report the comprehensive results of the first 10 years of experience in HSCT from the two major BMT units in Lebanon: Makassed University Hospital and the American University...

  • Combination of bone marrow stromal cell transplantation with mobilization by granulocyte-colony stimulating factor promotes functional recovery after spinal cord transection. Jie Luo; Hong-tian Zhang; Xiao-dan Jiang; Shan Xue; Yi-quan Ke // Acta Neurochirurgica;Nov2009, Vol. 151 Issue 11, p1483 

    Spinal cord injury (SCI) results in severe neurological deficit. However, the functional recovery following SCI is very poor due to the neural lost and limited axonal regeneration. To date, there was no effective treatment. Recent studies have shown that bone marrow stromal cells (BMSCs)...

  • Application of Mesenchymal Stromal Cells in Bone Marrow Transplantation for Sensitized Recipients. Xu, Lu-Hong; Fang, Jian-Pei; Hong, Dong-Ling; Wu, Yan-Feng // Acta Haematologica;2012, Vol. 127 Issue 2, p105 

    Sensitized patients are at high risk for graft rejection during transplantation. It is of interest to investigate the effect of mesenchymal stromal cells (MSCs) in sensitized hematopoietic stem cell transplantation. MSCs were generated from bone marrow cells of BALB/c mice. The molecular markers...

  • Neurological Complications after Allogeneic Transplantation – Can We Do Better? Dowling, Mark R.; Ballen, Karen K. // Acta Haematologica;2019, Vol. 142 Issue 4, p193 

    Neurological complications remain a devastating and feared complication after hematopoietic cell transplantation, and a significant source of morbidity and mortality. Significantly, the development of neurologic complications portended a poorer prognosis, with increased non-relapsed mortality,...

  • Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells. Goldstein, Gal; Toren, Amos; Nagler, Arnon // Current Pharmaceutical Design;May2007, Vol. 13 Issue 13, p1363 

    Human umbilical cord blood (CB) has established itself as a legitimate source for hematopoeitic stem cell transplantations. Since the first transplantation was preformed in 1988, it is estimated that approximately 4,000 patients, with malignant and non-malignant diseases, were transplanted with...

  • Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Cheuk, D. K. L.; Wang, P.; Lee, T. L.; Chiang, A. K. S.; Ha, S. Y.; Lau, Y. L.; Chan, G. C. F. // Bone Marrow Transplantation;Nov2007, Vol. 40 Issue 10, p935 

    A cohort of 138 children with 144 hematopoietic stem cell transplantation (HSCT) performed in 1997–2006 were analyzed to evaluate risk factors and mortality predictors of hepatic veno-occlusive disease (VOD). Nineteen patients (13.2%) developed VOD (nine boys, median age 3.5 years) at...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics